SOUTH JORDAN, Utah—Benjamin Landry, General Counsel at Health Catalyst , Inc. (NASDAQ:HCAT), recently sold 19,268 shares of the company's common stock. The transaction, executed on December 6, 2024, was part of a pre-established trading plan under Rule 10b5-1. Health Catalyst, with a market capitalization of $509 million, maintains a "GOOD" overall financial health score according to InvestingPro analysis.
The shares were sold at an average price of $8.3192 each, resulting in a total transaction value of $160,294. Following this sale, Landry retains ownership of 72,250 shares in the company. While currently unprofitable, analysts expect Health Catalyst to turn profitable this year, with the stock currently trading below its Fair Value based on InvestingPro metrics.
This transaction was conducted as part of a trading plan that Landry adopted in March 2024, ensuring compliance with insider trading regulations. Discover more insights about Health Catalyst and access detailed Pro Research Reports covering 1,400+ US stocks with an InvestingPro subscription.
In other recent news, Health Catalyst has disclosed its third-quarter financial results for 2024, indicating a positive profit and loss execution with a revenue mix shifting back towards software. In relation to this, financial services firms Piper Sandler and Stephens have updated their outlooks on the company. Piper Sandler has raised the target price for Health Catalyst to $12, up from $11, maintaining an Overweight rating on the company's stock. This adjustment is based on the firm's anticipation of a robust year-over-year growth of approximately 50% in adjusted EBITDA for calendar year 2025.
Simultaneously, Stephens has increased the target price for Health Catalyst to $9, up from $7, while maintaining an Equal Weight rating. This adjustment follows Health Catalyst's third-quarter performance, which included a modest EBITDA beat and an affirmation of its full-year 2024 bookings forecast. Moreover, Health Catalyst's leadership team, including CEO Dan Burton, CFO Jason Alger, and COO Dan LeSueur, has expressed a positive outlook for the company's growth trajectory and provided financial projections for the remainder of 2024 and the full year of 2025.
These are the recent developments for Health Catalyst, as the company continues to navigate the dynamic healthcare landscape, focusing on its growth strategies and financial expectations. As the company continues to drive growth and deliver value, stakeholders will be closely watching its performance against the projections shared in these updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.